Advances in retinal imaging technology have largely contributed to the understanding of the natural history, prognostic markers and disease mechanisms of geographic atrophy (GA) due to age-related macular degeneration. There is still no therapy available to halt or slow the disease process. In order to evaluate potential therapeutic effects in interventional trials, there is a need for precise quantification of the GA progression rate. Fundus autofluorescence imaging allows for accurate identification and segmentation of atrophic areas and currently represents the gold standard for evaluating progressive GA enlargement. By means of high-resolution spectral-domain optical coherence tomography, distinct microstructural alterations related to GA can be visualized.

Geographic atrophy (GA) represents the atrophic late-stage manifestation of ‘dry’ age-related macular degeneration (AMD). It is responsible for approximately 35% of all cases with late AMD [1,2]. While the overall incidence of neovascular AMD is still higher than the incidence of GA, atrophic disease has recently been found to occur 4 times as often as neovascular AMD in individuals ≥85 years of age, reflecting its important impact on public health in aging populations [1]. Histopathological studies have revealed cell death of the retinal pigment epithelium (RPE), the outer neurosensory retina and the choriocapillaris in areas of GA [3,4]. The natural course of the disease is characterized by the development of atrophic areas that enlarge continuously over time and that are associated with a corresponding absolute scotoma [3,5,6]. Visual acuity highly depends on the extent of foveal involvement. While a breakthrough has been achieved in the therapy of neovascular AMD by intravitreally administered anti-vascular-endothelial-growth-factor [7], there is to date no means to counteract the progression of GA. Recently, various interventional trials have been initiated.

For diagnosing GA different imaging modalities are available: fundus photography, fluorescence angiography, fundus autofluorescence (FAF) and optical coherence tomography (OCT; fig. 1). These not only allow refined phenotyping, but are also indispensable means for documenting the natural history of the disease and for identifying possible therapeutic effects in ongoing trials. Novel imaging technologies such as FAF imaging have also been helpful in identifying prognostic factors for disease progression and moreover may contribute to the understanding of the pathogenetic pathways in GA.

Fig. 1

Multimodal imaging in GA due to AMD: fundus photography, fluorescein angiography, FAF and high-resolution spectral-domain OCT (from left to right); from Fleckenstein et al. [62], with kind permission from Springer Science+Business Media.

Fig. 1

Multimodal imaging in GA due to AMD: fundus photography, fluorescein angiography, FAF and high-resolution spectral-domain OCT (from left to right); from Fleckenstein et al. [62], with kind permission from Springer Science+Business Media.

Close modal

Fundus photography can be used to detect the presence of GA. In clinical trials, based on conventional fundus photographs, GA has been defined as a sharply demarcated area of apparent absence of the RPE, larger than 175 µm in diameter, with visible choroidal vessels and no neovascular AMD [5,8,9]. Reduction of retinal thickness due to loss of outer neurosensory cell layers can be visualized by means of stereo fundus photography.

Until recently, fundus photography has been regarded as standard method for the assessment of the slowly progressive disease process [10]. Indeed, the majority of epidemiological and natural history studies addressing the enlargement of GA areas over time have used color fundus photographs [5,10,11,12,13]. However, graders at reading centers have reported difficulty in reproducibly measuring atrophic patches due to intersubject variability of fundus pigmentation, media opacities and the presence of drusen or small satellites of atrophy [14,15,16]. Low contrast between the hypopigmented atrophic areas and the surrounding nonatrophic retina may in addition lead to difficulties in exact and reliable delineation.

In fluorescein angiography, atrophic patches appear as well-demarcated, hyperfluorescent areas resulting from increased visualization of the normal choroidal fluorescence due to loss of RPE cells, which would otherwise weaken the transmission of fluorescein fluorescence (window defect; fig. 1). As compared to fundus photography, this signal exhibits higher contrast levels for delineation. However, neovascular or fibrotic alterations as well as drusen or pigmentary changes may also lead to an increased fluorescence signal and hence may interfere with GA delineation.

In indocyanine green angiography (ICG-A), atrophic patches appear as discrete hypofluorescent areas [17] with loss of background fluorescence due to accompanying atrophy of the choriocapillaris. Large and deep choroidal vessels may still be visible. Outlining the area of atrophy appears to be more difficult in ICG-A than it is in fluorescein angiography.

Fluorescence angiography is an invasive technique associated with several risks for the examined patient. Furthermore, it is relatively time consuming and less appropriate for GA quantification than the noninvasive techniques as described below. However, fluorescence – and especially fluorescein – angiography can be useful in identifying choroidal neovascularization that may develop in the course of the disease process.

Multiple lines of experimental and clinical evidence indicate that excessive accumulation of lipofuscin (LF) in postmitotic RPE cells together with its toxic components such as N-retinylidene-N-retinylethanolamine plays a role in the pathogenesis of GA associated with AMD [18,19,20]. LF is thought to mainly derive from the incomplete digestion of photoreceptor outer segments. It accumulates in the lysosomal compartment of RPE cells with age [21] and also in various complex and monogenetic retinal diseases including Best’s disease, Stargardt’s disease and AMD [19]. As yet it has not been completely understood why physiological LF accumulation with age leads to pathological findings and onset of retinal diseases in only some individuals.

FAF represents an imaging modality capable of reflecting the morphological changes associated with this common downstream pathogenetic pathway. It allows for topographic in vivo imaging of intrinsic fluorophores in the retina in a non-time-consuming and noninvasive way [22]. Spectrophotometric analysis by Delori et al. [23] has shown that the in vivo FAF signal is mainly derived from RPE LF.

As opposed to the invasive fluorescein angiography and ICGA, the FAF signal intensity is much lower. Hence, for achieving good image quality with a sufficient signal-to-noise ratio, camera systems are required that (1) reduce autofluorescence (AF) signals from planes other than the RPE, (2) use high sensitivity levels and (3) are capable of averaging multiple single images during acquisition. With the advent of confocal scanning laser ophthalmoscopy (cSLO), it has been possible to combine these properties in one imaging device [22,24,25,26,27].

Using an excitation wavelength of 488 nm and an emission bandwidth of 500–700 nm, areas of GA exhibit very low to extinguished FAF signals (dark) as RPE cell death is accompanied by loss of LF, leading to high contrast between atrophy and the perilesional retina (fig. 1). Contrast levels rise even further by the commonly observed finding that the perilesional zone shows high FAF intensities. Perilesional FAF changes in particular appear to have pathogenetic relevance: areas of increased FAF and hence LF accumulation outside GA may be associated with variable degrees of retinal sensitivity loss and precede the development and enlargement of outer retinal atrophy (fig. 2) [28,29,30]. These findings correlate with experimental data suggesting that certain molecular compounds of LF such as N-retinylidene-N-retinylethanolamine possess toxic properties and may interfere with normal cell function [31,32,33].

Fig. 2

Progression of GA illustrated by FAF imaging and GA quantification over time. Areas are segmented (white lines) for quantification of total GA area. During a follow-up period of about 9 years, the atrophic area increased to about 4 times the size at baseline. Note that enlargement of GA dominantly takes place in areas where there is a high FAF intensity in the perilesional zone at baseline; from Scholl et al. [37], with kind permission from PLoS One.

Fig. 2

Progression of GA illustrated by FAF imaging and GA quantification over time. Areas are segmented (white lines) for quantification of total GA area. During a follow-up period of about 9 years, the atrophic area increased to about 4 times the size at baseline. Note that enlargement of GA dominantly takes place in areas where there is a high FAF intensity in the perilesional zone at baseline; from Scholl et al. [37], with kind permission from PLoS One.

Close modal

High contrast to the perilesional nonatrophic retina allows for exact delineation and segmentation of atrophic areas using gray-value-based region-growing algorithms in semiautomated software [6,34]. Further development has recently resulted in the RegionFinder software by Heidelberg Engineering, Germany, for the existing Heidelberg Eye Explorer software (fig. 3). This novel image-processing tool allows for reproducible and rapid semiautomated detection and measurement of the size and progression of atrophic GA areas [35]. Its functions comprise direct export and alignment of recorded images, semiautomated identification of atrophic patches after selecting a seeding point and adjusting tolerance levels, shadow correction, semiautomated vessel detection and creation of a report form displaying the results of the analysis. Its application is not only suitable for analysis of progression rates in natural history studies or interventional trials aiming to slow down the disease process, but also for routine use in daily life, documenting disease progression in each individual patient.

Fig. 3

Semiautomated quantification of GA by means of image analysis software (RegionFinder, Heidelberg Engineering, Germany). Areas of atrophy can be quantified in a precise, reproducible and time-effective way. In this example, the difference image on the right shows the enlargement of GA between baseline (left) and the follow-up visit (middle); from Fleckenstein et al. [63], with kind permission from Springer Science+Business Media.

Fig. 3

Semiautomated quantification of GA by means of image analysis software (RegionFinder, Heidelberg Engineering, Germany). Areas of atrophy can be quantified in a precise, reproducible and time-effective way. In this example, the difference image on the right shows the enlargement of GA between baseline (left) and the follow-up visit (middle); from Fleckenstein et al. [63], with kind permission from Springer Science+Business Media.

Close modal

However, quantification of GA based on FAF images alone may be challenging. This is mainly due to low FAF intensities in the fovea because of absorption of short-wavelength light by foveal pigment. Utilizing corresponding blue reflectance (488 nm) and near-infrared reflectance (820 nm) images may help to improve discrimination of foveal lesion boundaries.

In various longitudinal natural history studies, high interindividual variation of atrophy progression has been independently reported, which cannot be explained by any of the demographic factors analyzed so far [10,12,13,27]. There is evidence that more specific individual or eye characteristics may at least in part be able to explain interindividual variability in the spread of atrophy. The FAM (Fundus Autofluorescence in Age-related Macular Degeneration, www.clinicaltrials.gov, NCT00393692) study group has identified different phenotypic patterns of abnormal FAF in the junctional zone of GA based on cSLO FAF imaging and described a step-wise classification approach (fig. 4) [27,36]. Analysis on longitudinal FAF imaging data on 195 eyes of 129 patients has shown prognostic relevance of these patterns for GA enlargement over time [27].

Fig. 4

Dominant phenotypic patterns of abnormal FAF in the junctional zone of GA based on cSLO FAF imaging. These patterns have prognostic relevance for the disease progression in terms of atrophy enlargement over time. While those patterns with only little change in FAF intensities surrounding GA predispose for slow progression, the banded and all diffuse patterns representing a more pronounced increase in FAF are frequently accompanied with high progression rates; GPS = fine granular with peripheral punctate spots; from Fleckenstein et al. [63], with kind permission from Springer Science+Business Media.

Fig. 4

Dominant phenotypic patterns of abnormal FAF in the junctional zone of GA based on cSLO FAF imaging. These patterns have prognostic relevance for the disease progression in terms of atrophy enlargement over time. While those patterns with only little change in FAF intensities surrounding GA predispose for slow progression, the banded and all diffuse patterns representing a more pronounced increase in FAF are frequently accompanied with high progression rates; GPS = fine granular with peripheral punctate spots; from Fleckenstein et al. [63], with kind permission from Springer Science+Business Media.

Close modal

Atrophy progression rates were slowest in eyes without abnormal FAF in the perilesional zone (median 0.38 mm2/year) followed by eyes with focal increased FAF (median 0.81 mm2/year). Enlargement rates were higher in eyes with a more pronounced increase in FAF such as the banded (median 1.81 mm2/year) or diffuse (median 1.77 mm2/year) patterns. The comparison of progression rates between the groups ‘none’ or ‘focal’ on the one hand and ‘banded’ or ‘diffuse’ on the other hand revealed a statistically significant difference (p < 0.0001). Although these patterns may reflect heterogeneity on a molecular, cellular or genetic level, significant risk loci for susceptibility of GA in AMD appear to have no significant influence on GA progression [37]. Regarding the data retrieved by Schmitz-Valckenberg et al. [38] and Bearelly et al. [39] on the amount of increased FAF around atrophy and its influence on atrophy enlargement, all these findings underline the hypothesis of LF accumulation causing RPE cell death. Other prognostic factors for GA progression have also been described, i.e. the knowledge of prior enlargement rates [10] or the enlargement rate of the fellow eye [10,40], multifocal configuration of GA [13], baseline GA size [10,27] and the diagnosis of the fellow eye [Goebel AP, et al.: Invest Ophthalmol Vis Sci 2011, vol. 52, ARVO E-abstract 1682].

Natural history data and identification of high-risk characteristics have already and will further help to test novel interventions in clinical trials aiming to counteract the slowly progressive disease process. Based on the natural history data in the previous studies, it appears that the GA progression rate has been approved by the Food and Drug Administration as primary outcome measure in clinical trials on GA [41].

Recently, FAF imaging using a different wavelength has been described as near-infrared AF using the ICGA mode of the cSLO without dye injection (excitation: 790 nm, emission >810 nm) [42,43]. Herein, melanin in the RPE seems to be the dominant source of the signal besides a varying signal from the choroid. However, contribution of other fluorophores cannot be excluded [42,44]. Comparative imaging with both modalities (AF 488 nm and AF 790 nm) exhibited a decreased signal over atrophic areas in both cases. The contrast to non-atrophic surrounding retina was more pronounced, however, in images of AF 488 than in AF 790 nm [44]. Also, the two imaging techniques reveal distinct AF changes in the perilesional zone of atrophy, but these abnormalities differ between both modes [42,44,45]. Further longitudinal analysis is needed to evaluate whether near-infrared AF is able to identify additional high-risk markers for disease progression.

An alternative method to acquire FAF images is the use of a fundus camera (FC). In order to reduce its disadvantage of not using confocal optics and hence being prone to detection of fluorescence from all tissue levels in the light beam, e.g. the lens, a modified FC with adjusted excitation and barrier filters has been proposed by Spaide (excitation 500–610 nm, emission 675–715 nm) [46]. Comparing FAF images recorded with the modified FC and with the cSLO suggests that the agreements for atrophy quantification are similar with both techniques. However, the FC seems to be inferior in capturing distinct FAF changes in the perilesional zone and hence in detecting prognostic markers for GA progression [47].

High-resolution spectral-domain OCT (SD-OCT) has provided new insights into various microstructural alterations associated with GA [48,49,50,51,52,53,54,55]. Anatomical sites of particular interest are the atrophic area itself as well as the perilesional retinal tissue. SD-OCT imaging revealed a wide spectrum of morphological abnormalities at both sites. As a common finding, within the atrophic lesions, SD-OCT bands 1, 2, 3 and 4 (corresponding to anatomical layers including the external limiting membrane, the inner-segment/outer-segment layer, and the RPE/Bruch’s membrane complex) as well as the assumed outer nuclear layer are usually absent [50].

Polarization-sensitive SD-OCT seems to be able to give even more detailed insights into the integrity of the RPE [56,57]. Ahlers et al. [58] illustrated that the intrinsic tissue property of the RPE to depolarize backscattered light can be used to clearly identify this cell layer even in the presence of severe distortions of the physiological retinal structure. In areas of GA they observed loss of polarization, along with patterns of depolarizing signals in deeper layers.

Simultaneous recording of cSLO and SD-OCT images in one instrument with an exact topographic overlay during image acquisition allows for correlation of pathological findings in different imaging modalities and accurate orientation of cross-sectional SD-OCT scans at anatomical sites of interest. Furthermore, serial examinations at the same anatomical location over time can be acquired [51,52,55]. Comparing FAF changes in GA eyes with simultaneously acquired SD-OCT scans, Schmitz-Valckenberg et al. [54] could show that the mean length of an atrophic lesion measured in the FAF image showed closest agreement with the disruption of choroidal hyperreflectivity as recorded in the SD-OCT scan, demonstrating that the severe reduction of the FAF signal is spatially correlated with the abrupt transition from a hyporeflective to hyperreflective area in the choriocapillaris below Bruch’s membrane on the SD-OCT scan presumably due to the loss of the RPE layer. Recently, there have been promising approaches to planimetrically measure the area of GA by detecting pathological findings in the correspondent SD-OCT-scans. However, it needs to be further evaluated which of the multiple pathological changes in B scans of GA eyes should be graded to obtain equivalent planimetric measurements in FAF. Sayegh et al. [59] showed that the area of complete choroidal signal enhancement in the SD-OCT B scans correlated best with the hypofluorescent area measured in FAF.

Using SD-OCT technology, the dynamic nature of development and progression of atrophy can be longitudinally analyzed in the same eye on a 3-dimensional level. Microstructural changes such as the advancing loss of the RPE and photoreceptor bands at the GA border or the subsequent apposition of the outer plexiform layer with Bruch’s membrane within the atrophic lesion have recently been described (fig. 5) [51]. Quantification of the lateral spread of GA by documenting the change in GA border position over time in longitudinal B scans at the same anatomical site showed a median spread of 106.90 µm/year (fig. 6) [51]. However, there was high variability not only between different patients, but also between different scan directions in the same eye. By this it can be assumed that specific local factors may influence GA growth [51]. This approach may be helpful both for monitoring the natural course of the disease and to elucidate pathogenetic mechanisms. In particular, the identification of structural risk factors reflecting disease activity and future GA progression may be important for prognosis and visual function.

Fig. 5

Progression of GA illustrated with high-resolution SD-OCT over a time period of 14 months. Progressive loss of the RPE layer (inner part of band 4), interface of the inner and outer segments of the photoreceptor layer (IPRL; band 2) and external limiting membrane (ELM; band 1) as well as thinning of the outer nuclear layer (ONL) at the border of atrophy are accompanying GA enlargement. Within the atrophic lesion, the remaining part of band 4 becomes more homogeneous, and the ONL progressively thins. Finally the outer plexiform layer (OPL) seems to lie directly adjacent to the outer part of band 4; BM = Bruch’s membrane; from Fleckenstein et al. [51], with kind permission from the Association for Research in Vision and Ophthalmology.

Fig. 5

Progression of GA illustrated with high-resolution SD-OCT over a time period of 14 months. Progressive loss of the RPE layer (inner part of band 4), interface of the inner and outer segments of the photoreceptor layer (IPRL; band 2) and external limiting membrane (ELM; band 1) as well as thinning of the outer nuclear layer (ONL) at the border of atrophy are accompanying GA enlargement. Within the atrophic lesion, the remaining part of band 4 becomes more homogeneous, and the ONL progressively thins. Finally the outer plexiform layer (OPL) seems to lie directly adjacent to the outer part of band 4; BM = Bruch’s membrane; from Fleckenstein et al. [51], with kind permission from the Association for Research in Vision and Ophthalmology.

Close modal
Fig. 6

Quantification of lateral spread of GA in an SD-OCT scan. Combined imaging with cSLO and SD-OCT allows for follow-up examinations exactly at the same location as the baseline examination. Longitudinal analysis reveals spread of atrophy measured by documenting GA border position; from Fleckenstein et al. [63], with kind permission from Springer Science+Business Media.

Fig. 6

Quantification of lateral spread of GA in an SD-OCT scan. Combined imaging with cSLO and SD-OCT allows for follow-up examinations exactly at the same location as the baseline examination. Longitudinal analysis reveals spread of atrophy measured by documenting GA border position; from Fleckenstein et al. [63], with kind permission from Springer Science+Business Media.

Close modal

There have also been different approaches using the SD-OCT to document GA area and progression by creating an en face fundus image similar to that produced by the cSLO on the basis of multiple side-by-side B scans [53,60,61,62]. First results are promising, but further analysis appears mandatory. Using OCT en face fundus images, Yehoshua et al. [61] examined 86 eyes of 64 patients and found a mean total GA area at baseline of 4.59 mm2. They reported high reproducibility and intergrader agreement. In contrast to the acquisition of FAF images with the cSLO, here only one type of scan is needed for documenting both en face and cross-sectional images.

A.P. Göbel, Heidelberg Engineering, F; M. Fleckenstein, Heidelberg Engineering, Optos Ltd., F; Heidelberg Engineering, R; S. Schmitz-Valckenberg, Heidelberg Engineering, Optos Ltd, Topcon UK, F; Heidelberg Engineering, R; C.K. Brinkmann, Heidelberg Engineering, F; F.G. Holz, Heidelberg Engineering, Optos Ltd., F; Heidelberg Engineering, Zeiss MediTec AG, C; Heidelberg Engineering, R (F = Financial Support; R = Recipient; C = Consultant).

1.
Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE: Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007;114:253–262.
2.
Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Bentham G, Rahu M, Vioque J, Young IS, Fletcher AE: Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006;124:529–535.
3.
Sarks SH: Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol 1976;60:324–341.
4.
Green WR, Enger C: Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmermann lecture. Ophthalmology 1993;100:1519–1535.
5.
Lindblad AS, Lloyd PC, Clemons TE, Gensler GR, Ferris FL 3rd, Klein ML, Armstrong JR: Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report No 26. Arch Ophthalmol 2009;127:1168–1174.
6.
Schmitz-Valckenberg S, Jorzik J, Unnebrink K, Holz FG: Analysis of digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:73–78.
7.
Grisanti S, Tatar O: The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008;27:372–390.
8.
Age-Related Eye Disease Study Research Group: The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study report No 6. Am J Ophthalmol 2001;132:668–681.
9.
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367–374.
10.
Sunness JS, Margalit E, Srikurnaran D, Applegate CA, Tian Y, Perry D, Hawkins B, Bressler NM: The long-term natural history of geographic atrophy from age-related macular degeneration. Ophthalmology 2007;114:271–277.
11.
Schatz H, McDonald HR: Atrophic macular degeneration: rate of spread of geographic atrophy and visual loss. Ophthalmology 1989;96:1541–1551.
12.
Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian Y, Hawkins B, Barron Y, Bergman A: Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106:1768–1779.
13.
Klein R, Meuer SM, Knudtson MD, Klein BE: The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. Am J Ophthalmol 2008;146:692–699.
14.
Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA: Measuring geographic atrophy in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 1999;40:1761–1769.
15.
Scholl HP, Peto T, Dandekar S, Bunce C, Xing W, Jenkins S, Bird AC: Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003;241:39–47.
16.
Pirbhai A, Sheidow T, Hooper P: Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration. Am J Ophthalmol 2005;139:455–461.
17.
Schneider U, Sherif-Adel S, Gelisken F, Kreissig I: Indocyanine green angiography and transmission defects. Acta Ophthalmol Scand 1997;75:653–656.
18.
Sparrow JR, Boulton M: RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595–606.
19.
Boulton M, Dayhaw-Barker P: The role of the retinal pigment epithelium: topographical variation and ageing changes. Eye 2001;15:384–389.
20.
Schütt F, Davies S, Kopitz J, Holz FG, Boulton ME: Photodamage to human RPE cells by A2-E, a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 2000;41:2303–2308.
21.
Feeney-Burns L, Hilderbrand ES, Eldridge S: Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci 1984;25:195–200.
22.
Von Rückmann A, Fitzke FW, Bird AC: Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol 1995;79:407–412.
23.
Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ: In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718–729.
24.
Bellmann C, Holz FG, Schapp O, Völcker HE, Otto TP: Topography of fundus autofluorescence with a new confocal scanning laser ophthalmoscope (in German). Ophthalmologe 1997;94:385–391.
25.
Von Rückmann A, Fitzke FW, Bird AC: Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci 1997;38:478–486.
26.
Solbach U, Keilhauer C, Knabben H, Wolf S: Imaging of retinal autofluorescence in patients with age-related macular degeneration. Retina 1997;17:385–389.
27.
Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HPN, Schmitz-Valckenberg S: Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143:463–472.
28.
Holz FG, Bellman C, Staudt S, Schütt F, Völcker HE: Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001;42:1051–1056.
29.
Schmitz-Valckenberg S, Bultmann S, Dreyhaupt J, Bindewald A, Holz FG, Rohrschneider K: Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:4470–4476.
30.
Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, Holz FG: Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol 2009;54:96–117.
31.
Bergmann M, Schütt F, Holz FG, Kopitz J: Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration. FASEB J 2004;18:562–564.
32.
Schutt F, Bergmann M, Holz FG, Kopitz J: Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003;44:3663–3668.
33.
Sparrow JR, Kim SR, Wu Y: Experimental approaches to the study of A2E, a bisretinoid lipofuscin chromophore of retinal pigment epithelium. Methods Mol Biol 2010;652:315–327.
34.
Deckert A, Schmitz-Valckenberg S, Jorzik J, Bindewald A, Holz FG, Mansmann U: Automated analysis of digital fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration using confocal scanning laser ophthalmoscopy (cSLO). BMC Ophthalmol 2005;5:8.
35.
Schmitz-Valckenberg S, Brinkmann CK, Alten F, Herrmann P, Stratmann N, Göbel AP, Fleckenstein M, Diller M, Jaffe GJ, Holz FG: Semi-automated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; E-pub ahead of print.
36.
Bindewald A, Schmitz-Valckenberg S, Jorzik JJ, Dolar-Szczasny J, Sieber H, Keilhauer C, Weinberger AW, Dithmar S, Pauleikhoff D, Mansmann U, Wolf S, Holz FG: Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration. Br J Ophthalmol 2005;89:874–878.
37.
Scholl HP, Fleckenstein M, Fritsche LG, Schmitz-Valckenberg S, Gobel A, Adrion C, Herold C, Keilhauer CN, Mackensen F, Mossner A, Pauleikhoff D, Weinberger AW, Mansmann U, Holz FG, Becker T, Weber BH: CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 2009;4:e7418.
38.
Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J, Wolf S, Scholl HP, Holz FG: Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006;47:2648–2654.
39.
Bearelly S, Khanifar AA, Lederer DE, Lee JJ, Ghodasra JH, Stinnett SS, Cousins SW: Use of fundus autofluorescence images to predict geographic atrophy progression. Retina 2011;31:81–86.
40.
Fleckenstein M, Adrion C, Schmitz-Valckenberg S, Gobel AP, Bindewald-Wittich A, Scholl HP, Mansmann U, Holz FG: Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 2010;51:637–642.
41.
Csaky KG, Richman EA, Ferris FL 3rd: Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2008;49:479–489.
42.
Keilhauer CN, Delori FC: Near-infrared autofluorescence imaging of the fundus: visualization of ocular melanin. Invest Ophthalmol Vis Sci 2006;47:3556–3564.
43.
Weinberger AW, Lappas A, Kirschkamp T, Mazinani BA, Huth JK, Mohammadi B, Walter P: Fundus near infrared fluorescence correlates with fundus near infrared reflectance. Invest Ophthalmol Vis Sci 2006;47:3098–3108.
44.
Schmitz-Valckenberg S, Lara D, Nizari S, Normando EM, Guo L, Wegener AR, Tufail A, Fitzke FW, Holz FG, Cordeiro MF: Localisation and significance of in vivo near-infrared autofluorescent signal in retinal imaging. Br J Ophthalmol 2011;95:1134–1139
45.
Kellner U, Kellner S, Weinitz S: Fundus autofluorescence (488 nm) and near-infrared autofluorescence (787 nm) visualize different retinal pigment epithelium alterations in patients with age-related macular degeneration. Retina 2010;30:6–15.
46.
Spaide RF: Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110:392–399.
47.
Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, Sehmi K, Fitzke FW, Holz FG, Tufail A: Evaluation of autofluorescence imaging with the scanning laser ophthalmoscope and the fundus camera in age-related geographic atrophy. Am J Ophthalmol 2008;146:183–192.
48.
Bearelly S, Chau FY, Koreishi A, Stinnett SS, Izatt JA, Toth CA: Spectral domain optical coherence tomography imaging of geographic atrophy margins. Ophthalmology 2009;116:1762–1769.
49.
Brar M, Kozak I, Cheng L, Bartsch DU, Yuson R, Nigam N, Oster SF, Mojana F, Freeman WR: Correlation between spectral-domain optical coherence tomography and fundus autofluorescence at the margins of geographic atrophy. Am J Ophthalmol 2009;148:439–444.
50.
Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Finger RP, Scholl HP, Loeffler KU, Holz FG: High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:4137–4144.
51.
Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Kramer I, Eter N, Helb HM, Brinkmann CK, Charbel Issa P, Mansmann U, Holz FG: Tracking progression with spectral-domain optical coherence tomography in geographic atrophy caused by age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:3846–3852.
52.
Helb HM, Charbel Issa P, Fleckenstein M, Schmitz-Valckenberg S, Scholl HP, Meyer CH, Eter N, Holz FG: Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol 2010;88:842–849.
53.
Lujan BJ, Rosenfeld PJ, Gregori G, Wang F, Knighton RW, Feuer WJ, Puliafito CA: Spectral domain optical coherence tomographic imaging of geographic atrophy. Ophthalmic Surg Lasers Imaging 2009;40:96–101.
54.
Schmitz-Valckenberg S, Fleckenstein M, Helb HM, Charbel Issa P, Scholl HP, Holz FG: In vivo imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2009;50:3915–3921.
55.
Wolf-Schnurrbusch UE, Enzmann V, Brinkmann CK, Wolf S: Morphologic changes in patients with geographic atrophy assessed with a novel spectral OCT-SLO combination. Invest Ophthalmol Vis Sci 2008;49:3095–3099.
56.
Pircher M, Goetzinger E, Leitgeb R, Hitzenberger C: Three dimensional polarization sensitive OCT of human skin in vivo. Opt Express 2004;12:3236–3244.
57.
Pircher M, Gotzinger E, Findl O, Michels S, Geitzenauer W, Leydolt C, Schmidt-Erfurth U, Hitzenberger CK: Human macula investigated in vivo with polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci 2006;47:5487–5494.
58.
Ahlers C, Gotzinger E, Pircher M, Golbaz I, Prager F, Schutze C, Baumann B, Hitzenberger CK, Schmidt-Erfurth U: Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:2149–2157.
59.
Sayegh RG, Simader C, Scheschy U, Montuoro A, Kiss C, Sacu S, Kreil DP, Prunte C, Schmidt-Erfurth U: A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy. Ophthalmology 2011, E-pub ahead of print.
60.
Jiao S, Knighton R, Huang X, Gregori G, Puliafito C: Simultaneous acquisition of sectional and fundus ophthalmic images with spectral-domain optical coherence tomography. Opt Express 2005;13:444–452.
61.
Yehoshua Z, Rosenfeld PJ, Gregori G, Feuer WJ, Falcao M, Lujan BJ, Puliafito C: Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011;118:679–686.
62.
Yehoshua Z, Rosenfeld PJ, Gregori G, Penha F: Spectral domain optical coherence tomography imaging of dry age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2010;41(suppl):S6–S14.
63.
Fleckenstein M, Wolf-Schnurrbusch U, Wolf S, von Strachwitz C, Holz FG, Schmitz-Valckenberg S: Imaging diagnostics of geographic atrophy (in German). Ophthalmologe 2010;107:1007–1015.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.